As per annexure enclosed
Awaiting price reaction for this filing.
Apollo Hospitals reported audited standalone revenue of Rs 8,202 crore for FY25, up 12.8% from Rs 7,274 crore in FY24, with standalone PAT rising 28.3% to Rs 1,296 crore from Rs 1,011 crore. Consolidated revenue grew 14.4% to Rs 21,794 crore and consolidated PAT jumped 61% to Rs 1,505 crore from Rs 935 crore. Q4 standalone PAT grew strongly at ~39.6% YoY to Rs 333 crore. The Board declared a final dividend of Rs 10 per share (200%), taking total FY25 dividend to Rs 19 per share (380%), payable by September 10, 2025. The Board also approved acquiring an existing 200-bed hospital asset for Rs 285 crore and re-appointed Executive Directors and an Independent Director. Credit rating was reaffirmed at AA+ with stable outlook by both CRISIL and India Ratings.
Strong double-digit profit growth, especially the 61% jump in consolidated PAT, signals robust operational performance and should be viewed positively by shareholders. The total Rs 19/share dividend offers a healthy yield, while the Rs 285 crore hospital acquisition and AA+ rating reaffirmation support the growth and credit narrative.